ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma

Annals of Oncology

Volumn 16, Issue SUPPL. 1, 2005, Pages

  Jost, L M ^a,d   Jelic, S ^b,d   Purkalne, G ^c,d  

^a KANTONSSPITAL   (Switzerland)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^c PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^d ESMO Head Office   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; MELPHALAN; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR; VINDESINE;

ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MELANOMA; METASTASIS; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL TECHNIQUE; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 21044454446     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi809     Document Type: Article

References (14)

1. National Institutes of Health Consensus Conference. Diagnosis and treatment of early melanoma. JAMA 1992; 288: 1314-1319.
2. Wagner JD, Schauwecker DS, Davidson D et al. Prospective study of FDG-PET imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17: 1508-1515.
3. AJCC (American Joint Committee on Cancer) Cancer Staging Handbook: TNM Classification of Malignant Tumors, sixth edition. New York: Springer-Verlag 2002.
4. Balch CM, Soong SJ, Smith T et al. Long-term results of a prospective surgical trial comparing 2cm vs. 4cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001; 8: 101-108.
5. Thomas JM, Newton-Bishop J et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757-766.
6. Cascinelli N, Morabito A, Santinami M et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. WHO Melanoma Programme. Lancet 1998; 351: 793-796.
7. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 2004; 100: 1692-1698.
8. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon-a-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST-1684. J Clin Oncol 1996; 14: 7-17.
9. Hancock BW, Wheatley K, Harris S et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22: 53-61.
10. Trask PC, Paterson AG, Esper P, Pau J, Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004; 13: 526-536.
11. Lienard D, Eggermont AM, Koops HS et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502.
12. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
13. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004; 22: 4474-4485.
14. Shumate CR, Urist MM, Maddoy WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg. 1995; 221: 566-571.